The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, briefly discusses his talk at the 1st Annual MPN Workshop of the Carolinas, which focused on ruxolitinib for treating myeloproliferative neoplasms (MPNs). Although the agent changed the therapeutic landscape for patients with these malignancies, treatment-related adverse events, namely cytopenias, limit the doses that can be prescribed and subsequently affect the efficacy of the treatment. Additionally, patients who fail on ruxolitinib have a poor prognosis. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology; Research Funding: Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals.
